We want you to know the facts.
Here are answers to questions you may have.


Given the common nature of HPV17, it is likely that patients who have ever been sexually active have been infected with cervical HPV. Because most HPV infections are asymptomatic and clear within 1-2 years of acquisition, knowing a patient’s HPV status is of limited clinical value.

No FDA-approved HPV test is designed to detect all HPV infections. All FDA-approved HPV tests have a cut-off, and are designed to detect HPV infections that are clinically relevant and properly identify women at risk of developing cervical disease. Rest assured that the Aptima HPV test has shown no statistical difference in sensitivity when compared to DNA-based HPV tests.

The Aptima HPV test indications are the same as those for DNA based tests, and align with current guidelines.
The Aptima HPV test is indicated to screen women 21 years with ASCUS cytology to determine the need for colposcopy, and to screen women 30 years for high-risk HPV types.

ACOG has acknowledged that the RNA based test is acceptable, and has not indicated that it should be used any differently than DNA based tests.

The ACOG Practice Bulletin Committee acknowledges that the RNA test is acceptable for use with cervical cancer screening but was not included in the 2012 Practice Bulletin #131 because, “At the time the Practice Bulletin was being developed, only DNA based tests were available. The Committee acknowledged that the RNA test is also acceptable.”

The Aptima HPV 16, 18/45 genotype assay is the first FDA‐approved HPV genotype test to include type 45. Recent data suggests that although cervical cancer incidence has decreased since the 1970s, the prevalence of adenocarcinoma cases has risen approximately 32% in the same time frame.14 Detection of these HPV types as part of reflex testing may help clinicians identify up to 94% of all cervical adenocarcinomas.13

Although HPV genotype 45 is fairly uncommon, identified in only 0.4% of women with normal cytology, data indicates that it is the third most common HPV genotype in invasive cancer. The addition of HPV genotype 45 is designed to help identify more women at risk for adenocarcinoma, with minimal impact to colposcopy rates.

Yes, the Aptima HPV test has an internal control that controls for inhibition and instrument error.

The Aptima HPV test can detect a clinically relevant infection with a lower number of cells per milliliter (mL) compared to other HPV tests. The guiding bodies, such as the FDA, CDC, CAP, and others, recommend an internal control be used either through a house-keeping gene or a spiked in control. Aptima HPV has a spiked in control that meets this criteria.

Aptima HPV only requires 1 mL of specimen from a ThinPrep pap vial, compared to 4 mL for the HC2 assay. A decreased specimen requirement may result in few Quantity Not Sufficient (QNS) results for you and your patients.

In the context of cervical cancer screening, clinical sensitivity refers to the ability of the HPV test to detect a cervical lesion that is likely a precursor to cervical cancer. The definition of a true positive is the positive HPV result, in a patient with underlying cervical disease (CIN2+ lesion).

A recently published meta-analysis of clinical data for Aptima HPV as compared to digene Hybrid Capture (HC2) determined that the pooled sensitivity for Aptima among ASC-US patients was high (see table below).16 The authors further determined that, "Aptima is as sensitive as other currently used HPV DNA test systems for the detection of CIN2 or greater."16

(95% CI)
ASC-US Pooled
values CIN2 +
ASC-US Pooled
values CIN3 +
Aptima HPV95.7%
Hybrid Capture 293.8%

The NPV of an assay is a function of a number of factors, particularly its sensitivity and the prevalence of disease in the patient population under study. In the CLEAR trial, Aptima HPV was found to have a high NPV. The NPV of Aptima HPV was also found to be statistically similar to the NPV of digene HC2 HPV DNA assay.2 A high NPV provides confidence that the Aptima HPV assay will detect HPV infections that are putting patients at risk for developing cervical disease.

Negative Predictive
All biopsies
CIN2 +
(95% CI)
CIN3 +
(95% CI)
Aptima HPV97.8%
Hybrid Capture 297.7%

For more information, contact your sales representative
or call 1-866-MYQUEST (1-866-697-8378).